Novartis in the lead to acquire cancer drug developer MorphoSys, sources say – CNBC

Drug maker Novartis is in advanced talks to acquire MorphoSys, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 …

scroll to top